Drug intelligence / Profile preview

fosfomycin + imipenem

Development stage: Preclinical
Lead developer: Merck
Modality: Small Molecules
Administration: Intravenous

Overview

Fosfomycin + imipenem is an antibiotic combination therapy that demonstrates synergistic effects against various resistant bacterial pathogens. Fosfomycin inhibits bacterial cell wall synthesis by binding to UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), preventing peptidoglycan formation, while imipenem targets penicillin-binding proteins. This combination has shown particular efficacy against methicillin-resistant Staphylococcus aureus (MRSA), including glycopeptide-intermediate and daptomycin-nonsusceptible strains, as well as multidrug-resistant gram-negative bacteria like Acinetobacter baumannii. It has been studied as salvage therapy for serious infections.

Targets

MurA (UDP-N-acetylglucosamine 1-carboxyvinyltransferase)PBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on fosfomycin + imipenem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fosfomycin + imipenem.

Explore the full profile